AI technology company launches with Novartis and Sarepta deals11 May 2020
Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.
Dyno Therapeutics emerges from stealth with two strategic collaborations with Novartis and Sarepta to develop improved gene therapies with Adeno-Associated Virus (AAV vectors) based on artificial intelligence (AI) technology.
Novartis collaborationThe biotechnology company's deal with Novartis will focus on developing improved AAV vectors for research, development, and commercialization of gene therapies for ocular diseases.
The partnership will allow the parties to utilize Dyno’s CapsidMap AI platform along with Novartis expertise in ophthalmology and gene therapy development and global commercialization to deliver innovative gene therapies to patients with serious diseases of the eye.
According to Eric D. Kelsic, CEO and Co‑founder of Dyno Therapeutics, many eye diseases are particularly suitable for gene therapy treatment, and new and improved AAV vectors could open up more opportunities.
Dyno will use AI technology and its suite of machine learning and experimental tools for the design and discovery of novel AAV capsids, the cell-targeting protein shell of viral vectors, with improved functional properties for gene therapy.
Novartis will conduct preclinical, clinical, and commercialization activities for the gene therapy product candidates created with the novel AAV capsids.
Dyno will receive upfront consideration plus committed research funding and license fees. In addition, Dyno will be eligible to receive clinical, regulatory and sales milestone payments, as well as royalties on worldwide net sales of any commercial products developed through the partnership.
In a separate deal, Dyno and Sarepta Therapeutics will work together to develop next-generation AAV vectors for muscle diseases, also using Dyno’s CapsidMap platform.
AI and machine learning technologies have the potential to deliver enhanced vectors for gene therapies. Dyno’s proprietary CapsidMap platform offers new ways to identify novel capsids that could offer improved muscle targeting and immune-evading properties, in addition to advantages in packaging and manufacturing.
Under the terms of this agreement, Dyno will be responsible for the design and discovery of novel AAV capsids with improved functional properties for gene therapy whereas Sarepta will be responsible for conducting preclinical, clinical and commercialization activities for gene therapy product candidates using the novel capsids.
If successful, Dyno could receive more than $40 million in upfront, option and license payments during the research phase of the collaboration.
HKBU scientists develop technique to eliminate drug side effects
19 May 2020
The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.Read more
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit
18 May 2020
CDMO is contracted to produce multiple clinical batches from German facilityRead more
Characterizing virus and virus-like particles
12 May 2020
New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.Read more
Bio-Rad launches anti-certolizumab pegol antibodies
5 May 2020
Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.Read more
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report
13 Apr 2020
The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.Read more
AstraZeneca "incredibly excited" by lung cancer treatment trial
13 Apr 2020
Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.Read more
German pharma companies are meeting the corona "stress test"
7 Apr 2020
The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.Read more
World’s leading biobanks join a global network to advance personalized healthcare research
6 Apr 2020
The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.Read more
Servier strengthens its R&D pipeline with Symphogen acquisition
6 Apr 2020
Symphogen becomes the antibody center of excellence within Servier.Read more
Evotec expands into gene therapy with new Austrian unit
6 Apr 2020
Evotec has established a dedicated gene therapy-based R&D site in Orth an der Donau, Austria with the immediate focus of spearheading a partnership with Japan’s Takeda to support its research projects, the German drug discovery firm said Monday.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation